LACunar Intervention (LACI-2) Trial-2
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 363 participants.
Also called NCT03451591
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 2/3
- Enrolled
- 363 participants
- Registry
-
NCT03451591 -
2016-002277-35
-
- Other papers using this trial's data
- Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03451591. Randomized; single masking; primary purpose prevention. Start 2018-01-08 (actual); primary completion 2022-05-31 (actual). Results posted on 2024-11-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- LACunar Intervention (LACI-2) Trial-2
- Acronym
- LACI-2
- Condition
- Cerebral Small Vessel Diseases
- Condition
- Stroke, Lacunar
- Intervention (Drug)
- Isosorbide Mononitrate XL (ISMN)
- Intervention (Drug)
- Cilostazol
- Intervention (Drug)
- ISMN XL and Cilostazol
- Intervention (Other)
- Neither ISMN nor cilostazol
- Lead sponsor
- University of Edinburgh
- Collaborator
- British Heart Foundation
- Collaborator
- University of Nottingham
Record details
- Record id
cardio:ct-nct03451591- Content hash
8f599f38af40114559d9f5125511919155774dcaa2c8fcb1c7b5d108e1387585